AI assistant
X4 Pharmaceuticals, Inc — Director's Dealing 2024
Oct 8, 2024
34355_dirs_2024-10-08_c1a1d953-b787-4794-8645-a7ccba61da0f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2024-10-04
Reporting Person: Baldry Mark (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-10-04 | Common Stock | A | 34946 | — | Acquired | 59636 | Direct |
| 2024-10-07 | Common Stock | S | 11127 | $0.5847 | Disposed | 48509 | Direct |
Footnotes
F1: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition.
F2: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.561 to $0.6115, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.